Generic Oncology Drug Market: How Is the Lenalidomide Generic Market Creating a Landmark Commercial Event?
Lenalidomide generic entry — the 2022 US market entry of generic lenalidomide (Revlimid) following the Bristol-Myers Squibb/Celgene settlement creating volume-limited generic competition — represents the most commercially significant recent generic oncology drug market development, with the Generic Oncology Drug Market reflecting lenalidomide's generic market as a landmark...
0 Kommentare 0 Geteilt 140 Ansichten 0 Bewertungen
Gesponsert